Study* | Year | Antiplatelet | ACS type | Treatment | Morphine dosing | Group | Patient number | Age (year) | Male % | MI history % | DM % | HTN % | Smoking % |
Meine et al 10 | 2005 | Clopidogrel (40%) | NSTEMI | 66% had early angiogram | Intravenous on presentation | Morphine | 17 003 | 65 | 62 | 33 | 32 | 67 | 33 |
No morphine | 40 036 | 70 | 59 | 31 | 33 | 70 | 25 | ||||||
Puymirat et al 2 | 2016 | Clopidogrel (100%) | STEMI | PCI | Intravenous on presentation | Morphine | 453 | 59 | 81 | 11 | 12 | 39 | 53 |
No morphine | 1985 | 64 | 73 | 11 | 17 | 50 | 38 | ||||||
Kubica et al 5 | 2016 | Ticagrelor (100%) | STEMI and NSTEMI | PCI | Intravenous on presentation | Morphine | 35 | 61 | 66 | 14 | 23 | 43 | 55 |
No morphine | 35 | 63 | 80 | 23 | 14 | 60 | 45 | ||||||
Parodi et al 6 | 2015 | Ticagrelor (68%) and prasugrel (32%) | STEMI | PCI | Not specified | Morphine | 205 | 62 | 73 | 9 | 53 | 49 | 57 |
No morphine | 95 | 61 | 79 | 7 | 15 | 54 | 53 | ||||||
Bellandi et al 3 | 2016 | Ticagrelor (72%) and prasugrel (28%) | STEMI | PCI | Not specified | Morphine | 108 | 64 | 73 | 8 | 45 | 55 | 49 |
No morphine | 74 | 64 | 76 | 8 | 16 | 66 | 45 | ||||||
Mccarthy et al 9 | 2017 | Clopidogrel (77%) and ticagrelor (18%) | STEMI and NSTEMI | PCI | Not specified | Morphine | 783 | 62 | 76 | 31 | 28 | 68 | 30 |
No morphine | 2244 | 65 | 74 | 24 | 23 | 66 | 24 | ||||||
Bonin et al 7 | 2018 | Not specified | STEMI | PCI | Not specified | Morphine | 554 | 59 | 82 | 6 | 13 | 38 | 43 |
No morphine | 413 | 61 | 82 | 5 | 13 | 37 | 41 | ||||||
Farag et al 8 | 2018 | Clopidogrel (86%) and ticagrelor (14%) | STEMI | PCI | Intravenous prehospital | Morphine | 218 | 64 | 78 | 11 | 16 | 49 | 34 |
No morphine | 82 | 63 | 80 | 12 | 22 | 54 | 29 |
*All study reported in-hospital outcomes except Bonin et al.
ACS, acute coronary syndrome; NSTEMI, non-ST elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST elevation myocardial infarction.